In Section C, contributors will receive ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment right up until disorder progression or maybe the members are not able to tolerate the study drugs. - "Our study discovered the vital role on the KLF16/MYC https://clinical-trial-recruitmen69135.blog-mall.com/32631370/little-known-facts-about-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers